GN
Genmab A/S
GNMSF · OTC
$353.00 +1.80% (+$6.24)
1M +2.59%
Market Cap $21.3B
P/E Ratio 27.23x
Div. Yield -
ROE 13.49%
Bulios Fair Price
$478.07
35.4% upside
Current Price
$353
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GNMSF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
42 /100
Fair P/E 27.23x
P/FCF 24.50x
EV/EBITDA 18.41x
Growth
0 /100
Declining EPS growth 42.26%
Book val. growth 40.24%
Rev. growth 35.73%
Profitability
100 /100
Strong Gross margin 93.03%
FCF margin 21.13%
Net margin 19.02%
Quality
53 /100
Average ROIC 9.87%
Asset turnover 0.33x
ROE 13.49%
Debt
60 /100
Moderate Debt/Equity 0.89x
Net debt/EBITDA 2.76x
Current ratio 2.46x
Stability
40 /100
Moderate Beta 0.69x
Profitable years 6
Rev. volatility 60.78%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GNMSF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jan van de Winkel
Employees
3,029
Headquarters
Copenhagen
Upcoming events
05 NOV
Earnings
Upcoming earnings report